Skip to main content
. 2021 Mar 19;8(1):e001471. doi: 10.1136/openhrt-2020-001471

Figure 2.

Figure 2

Relative hazard of major bleeding (top panels) and death (bottom panels) in relation to predicted ABC-AF-bleeding (top) and ABC-AF-death (bottom) 1-year risks among patients from different regions in the ARISTOTLE (left panels) and RE-LY (right panels) trials. An arbitrary reference point is set at a predicted ABC-AF-risk value of 0.02 in Europe. The p value in each panel is for a test of no interaction between region and predicted ABC-AF-risk. ABC-AF bleeding score is age, biomarkers (troponin-hs, haemoglobin, and GDF-15 or renal function), clinical history (previous bleeding). ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy.